Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation after Chemoradiation in Unresectable Stage III ALK+ Non-Small Cell Lung Cancer Amin H. Nassar , Ritujith Jayakrishnan , Jamie Feng , Frances Shepherd , Elio Adib , Justin M. Cheung , Jessica J. Lin , Yufei Liu , Steven H. Lin , Kaushal Parikh , Arthi Sridhar , Purnima Shakya , Thomas J. Dilling , David Kaldas , Jhanelle E. Gray , Anastasiya Lobachov , Jair Bar , Heike Luders , Christian Grohe , Shruti Gupta , Ticiana Leal , Bailey Fitzgerald , Fionnuala Crowley , Yu Fujiwara , Thomas U. Marron , Molly Wilgucki , Joshua Reuss , Luxi Chen , Kamya Sankar , Jacqueline Aredo , Joel W. Neal , Heather A. Wakelee , Rohit Thummalapalli , Helena Yu , Ryan Whitaker , Ana Velazquez , Meera Ragavan , Alessio Cortellini , David J. Kwiatkowski , Abdul Rafeh Naqash , Sarah B. Goldberg , So Yeon Kim JOURNAL OF THORACIC ONCOLOGY（2025）
Key words
Immunotherapy, ALK inhibitors, Non-small cell lung cancer, Chemoradiation
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
